Wells Fargo upgraded Amwell (AMWL) to Overweight from Equal Weight with a $15 price target The firm says valuation buffer is sufficient to move off the sidelines. Wells thinks DHA plus cost cuts, divestitures and a new CFO are likely to positively re-rate Amwell in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell reiterates FY24 revenue view of $247M-$252M, consensus $249.88M
- Amwell divests virtual psychiatric care business for $21M and added earn-out
- Amwell Expands CFO Role Amid Leadership Transition
- Amwell COO Kurt Knight, chief commercial growth officer Kathy Weiler to depart
- Amwell price target lowered to $10.50 from $20 at Morgan Stanley